Information Provided By: 
Fly News Breaks for December 23, 2015
PSDV
Dec 23, 2015 | 08:27 EDT
Ladenburg analyst Matthew Kaplan raised pSivida's price target to $12.50 from $8 and reiterated his Buy rating following the "outstanding" top-line data for first Medidur Phase 3 trial in treating chronic noninfectious posterior uveitis. Kaplan said the data presents a strong case that the FDA may allow Medidur NDA filing without completion of the 2nd Phase 3 study.
News For PSDV From the Last 2 Days
There are no results for your query PSDV
